Developing Substrate Replacement Therapies
Glycomine is committed to developing therapeutics for serious rare diseases, the vast majority of which do not have any disease-modifying treatment options available. Its lead program, GLM101, is currently in clinical trials in the U.S. and Europe and has received Orphan Drug Designation (ODD) in the U.S. and Europe and Rare Paediatric Disease Designation (RPDD) in the US.
CEO Steven Axon
Advent Contact Dominic Schmidt
